GlaxoSmithKline (GSK) is expected to announce redundancies when it unveils a massive restructuring programme across its entire business later this spring. The move follows the merger of Glaxo Wellcome and SmithKline Beecham.
It is understood that marketing jobs are under threat as part of the company restructure, but a final announcement will not be made until later in the year.
Earlier this month, GSK announced a restructuring programme for its worldwide research and development divisions, designed to boost productivity and profitability. The overhaul will take place alongside a review of the company’s portfolio of drugs that are currently under research.
A spokeswoman for the company confirms that GSK will look at restructuring its entire business. She says: “Redundancies are inevitable and will be across the board. GSK is a newly merged company and some changes are expected to be made within the business.”
However, it is unknown where the largest proportion of the job losses will come from. The business is divided into consumer healthcare and pharmaceutical divisions. The GSK consumer healthcare business is divided into nutritional healthcare and over-the-counter medicines.
GSK recently announced a review of its £406m media buying account in the US but has denied that its global media account is up for review (MW February 8).